Asymmetric IgG antibodies induced by different immunotherapies in a murine model of allergy.
Specific immunotherapy (SIT) is the only potentially curative treatment for those allergic processes mediated by IgE. We compared the effects of different SITs in mice sensitised with ovalbumin (OVA) Al (OH)(3) : 1) OVA entrapped in particles of poly (D,L-lactic-co-glycolic acid) (PLGA-OVA), 2) Soluble OVA (OVA-sol) and 3) Polymerised OVA (OVA-pol). Serum levels of specific IgE, IgG1, IgG2a and asymmetric IgG, the cutaneous anaphylaxis test (PCA), and the IL-10, IFNgamma and IL-4 levels in culture supernatants of splenocytes challenged with OVA were assessed. Mice treated with PLGA-OVA had higher levels of asymmetric antibodies than non-desensitised mice; a low IgG1 and high IgG2a level was observed together with inhibitory effect in the PCA reaction that reversed in the absence of asymmetric IgG. IL-10 and IFNgamma levels were higher in supernatants from mice treated with PLGA-OVA and OVA-sol than those obtained from non-desensitised controls. Our results suggest that among the different SITs evaluated, PLGA-OVA is the one that best showed an increase in the asymmetric IgG molecules and an effective deviation of the immune response. Furthermore, the increase in the proportion of asymmetric antibodies would be of importance when designing new vaccination strategies for allergy.
Apicella
Carolina
C
Instituto de Estudios de la Inmunidad Humoral R.A. Margni (CONICET-UBA), Facultad de Farmacia y Bioquímica, (FFyB), Universidad de Buenos Aires (UBA), Argentina.
Rey Roldan
Estela
E
Chiappetta
Diego A
DA
Molinari
Claudia
C
Bregni
Carlos
C
Dokmetjian
José
J
Gentile
Teresa
T
D000818:Animals; D002478:Cells, Cultured; D002846:Chromatography, Affinity; D003888:Desensitization, Immunologic / Q000379:methods*; D004195:Disease Models, Animal; D006016:Glycolates / Q000276:immunology; D006967:Hypersensitivity / Q000097:blood / Q000276:immunology*; D007073:Immunoglobulin E / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood*; D007371:Interferon-gamma / Q000378:metabolism; D016753:Interleukin-10 / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D019344:Lactic Acid; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000276:immunology; D010323:Passive Cutaneous Anaphylaxis; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D013154:Spleen / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D013997:Time Factors
D006016:Glycolates; D007074:Immunoglobulin G; D016753:Interleukin-10; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D015847:Interleukin-4; D011100:Polyglycolic Acid; D019344:Lactic Acid; D007073:Immunoglobulin E; D007371:Interferon-gamma; D010047:Ovalbumin